Marc Turner | Medical Director
Scottish National Blood Transfusion Service

Marc Turner, Medical Director, Scottish National Blood Transfusion Service

Marc Turner is Professor of Cellular Therapy at the University of Edinburgh and Medical Director at the Scottish National Blood Transfusion Service. He qualified in Medicine from the University of Manchester in 1982 and trained in General Medicine and Haematology.  He obtained his PhD in human haematopoietic stem cell biology from the University of Edinburgh in 1995 and an MBA in Life Sciences from the Open University in 2007.  He is a Fellow of the Royal College of Physicians of London, of the Royal College of Physicians of Edinburgh, of the Royal College of Pathologists and of the Higher Education Academy. His research interests include the risk of transmission of prion diseases by blood, tissues and cells and the translation of advanced therapy medicinal products to clinical practice. He has held 37 research grants and has over 150 publications. He is currently a Non-Executive Director of Cell and Gene Therapy Catapult and Chair of the Global Alliance on iPSC Therapies. He is a former member of the UK Advisory Group on the Safety of Blood, Tissues and Organs (SaBTO) and has provided international advice on the risks and management of variant CJD transmission. He is also a former Member of the European Medicines Agency Committee on Advanced Therapies (CAT) and a current Member of the Commission on Human Medicines Clinical Trials, Biologicals and Vaccines Expert Advisory Group and the Scottish Medicines Consortium. He is co-Director of the Northern Alliance Advanced Therapy Treatment Centre covering Scotland and the North of England.


Pre-Conference Workshop Day - Monday 30th March 2020 @ 14:15

Global Alliance on iPSC Therapies: challenges in developing international consensus standards

  • If cellular therapy products derived from induced pluripotent stem cell (iPSC) lines are to be available across international regulatory jurisdictions then a common set of criteria need to be agreed for defining what constitutes clinical grade lines.
  • Similarly, if different iPSC lines are used for manufacture of a single cellular therapy product, for example in the autologous or HLA-matched allogeneic context, then comparability will need to be demonstrable.
  • GAiT has been working with international partners to develop a consensus set of quality guidelines for clinical grade iPSC lines and standardise the assays which support them.
last published: 04/Jun/20 08:25 GMT

back to speakers